Medicare Part D Coverage For Obesity Drugs Urged By House Appropriations Panel
In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.
You may also be interested in...
Eli Lilly’s drug could join Novo Nordisk’s Wegovy on the market in the next year or so as treatments offering significantly more weight loss than previous drugs have been able to. Could that open the door to greater access?
Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.